Dicerna to Present at the Stifel 2016 Healthcare Conference
10 November 2016 - 8:05AM
Business Wire
Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer
of investigational RNA interference (RNAi) therapeutics, today
announced that Douglas M. Fambrough, Ph.D., president and chief
executive officer, will present at the Stifel 2016 Healthcare
Conference on Wednesday, November 16, 2016, from 3:45-4:25 p.m. ET
at the Lotte New York Palace Hotel in New York.
A live webcast of the presentation can be accessed on the
Investors & Media section on the Dicerna website at
www.dicerna.com. An archived replay of the webcast will be
available on the Company’s website after the conference.
About Dicerna Pharmaceuticals, Inc.
Dicerna Pharmaceuticals, Inc., is a biopharmaceutical company
focused on the discovery and development of innovative RNA
interference (RNAi)-based therapeutics for rare diseases involving
the liver and for other diseases involving the liver such as
chronic liver diseases, cardiovascular diseases, and viral
infectious diseases. The Company is using its proprietary GalXC™
RNAi technology platform to build a broad pipeline in these core
therapeutic areas. Dicerna is pursuing target genes where
connections between target gene and diseases are well understood
and documented. The Company intends to discover, develop and
commercialize these novel therapeutics either on its own or in
collaboration with pharmaceutical partners.
For more information, please visit www.dicerna.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161109005920/en/
Investor:Rx Communications GroupMelody Carey,
917-322-2571mcarey@rxir.comorMedia:SmithSolveAlex Van Rees,
973-442-1555 ext. 111alex.vanrees@smithsolve.com
Dicerna Pharmaceuticals (NASDAQ:DRNA)
Historical Stock Chart
From Apr 2024 to May 2024
Dicerna Pharmaceuticals (NASDAQ:DRNA)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Dicerna Pharmaceuticals Inc (NASDAQ): 0 recent articles
More Dicerna Pharmaceuticals, Inc. (MM) News Articles